Pharming Group (NASDAQ:PHAR - Get Free Report) shares saw an uptick in trading volume on Friday . 9,009 shares traded hands during mid-day trading, an increase of 51% from the previous session's volume of 5,954 shares.The stock last traded at $8.40 and had previously closed at $8.86.
Wall Street Analysts Forecast Growth
PHAR has been the subject of several recent analyst reports. Jefferies Financial Group began coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th.
Read Our Latest Research Report on PHAR
Pharming Group Price Performance
The company's 50 day moving average is $9.17 and its 200 day moving average is $8.57. The stock has a market cap of $550.37 million, a price-to-earnings ratio of -31.12 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
